FDA greenlights Amgen’s Nplate for pediatric immune thrombocytopenia
Amgen’s Nplate (romiplostim) has received US Food and Drug Administration (FDA) approval for treating pediatric patients with immune thrombocytopenia (ITP). This latest approval extends the drug’s use to children aged one year and older. The FDA’s endorsement of Nplate for pediatric ITP patients marks a significant milestone in treating this rare autoimmune disorder, characterized by […]